IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
Oct. 02, 2024 8:00 AM ETAbbVie Inc. (ABBV) Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
(RTTNews) - Allergan plc (AGN) said that it received U.S. Food and Drug Administration approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula ...
Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...
Allergan Inc. is a step closer to expanding its lower-face filler lineup. The Irvine drug maker said this month that a Food and Drug Administration advisory committee voted that the benefits of its ...
Years ago, the beauty industry began focusing on properly proportioned facial features. First in trend was cheekbone definition, then the trend became lip-focused. While these areas have been the ...
The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple hallowing in individuals over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results